NDA 210833/S-001

SUPPLEMENT APPROVAL

Aquestive Therapeutics
Attention: Melina Cioffi, PharmD
Vice President Regulatory Affairs
30 Technology Drive
Warren, NJ 07059

Dear Dr. Cioffi:

Please refer to your Supplemental New Drug Application (sNDA) dated and received June 15, 2020, pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Sympazan (clobazam) Oral Films.

This "Changes Being Effected" supplemental new drug application provides for the following revisions to the drug product packaging for Sympazan™ (clobazam) oral film strips (5 mg, 10 mg, and 20 mg strength).

- a change in the shape of the primary container closure system, namely from pouches (sachets) made with (b) (4) to (b) (4)
- updates to the layout of the pouch labeling without changing the contents.

APPROVAL & LABELING

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CARTON AND CONTAINER LABELS

Submit final printed carton and container labels that are identical to enclosed carton and container labels, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission "**Product Correspondence – Final Printed Carton and Container Labels for approved NDA 210833/S-001.**" Approval of this submission by FDA is not required before the labeling is used.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Avani Patel, Regulatory Business Process Manager, at (240) 402 - 1845.

Sincerely,

{See appended electronic signature page}

Gurpreet Gill-Sangha, Ph.D.
Branch Chief, Branch 3
Division of Post-Marketing Activities I
Office of Lifecycle Drug Products
Office of Pharmaceutical Quality
Center for Drug Evaluation and Research

Enclosures:

Carton and Container Labeling

Gurpreet
Gill Sangha

Digitally signed by Gurpreet Gill Sangha
Date: 12/09/2020 02:51:19PM
GUID: 5135f2ad000117842392c50c36c7f28a